Overall, these results suggest that BET inhibition can be an effective strategy to counter DUX4 target gene expression in differentiating FSHD myotubes, with comparable effects to high dose losmapimod. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.